Advertisement

Blogs

Phamacogenomics - A Review of Current Literature

By Michael Maccia posted 06-22-2015 16:54

  
This month I completed the BCPS re-certification credit which dealt with issues in pharmacogenomics, an area in which I have very limited experience or knowledge. The module was a podcast from a presentation at an ASHP meeting. Initially, I was not too thrilled about sitting in front of the computer to listen to 2 hrs and 45 minutes of a podcast. After completion, even though the presentation was a little long, I was very happy with what I was able to learn from this experience. Coming in, I had very little knowledge of this intricacies of this subject; just a broad understanding, ie, dosing problems with warfarin and 2C9 and VKOR1.

The information presented was at a basic level, but it was not too basic. I left learning a lot about pharmacogenomics. This is a topic in which there seems to be a whole lot of research done, however, the clinical implications of this genetic monitoring has not been widely shown. Currently, oncology seems to be an area in which pharmacogenomics is used for multiple medications, but not really in any other subject fields. It will be interesting to see how pharmacogenomics expands over the course of my career. 

Some topics discussed were mutations in CYP 2D6, CYP 2C9, and VKOR1. There has been plenty of trials looking at the applicability of knowing patients mutations for medications such as SSRIs or warfarin, however these studies have not shown this information has a role in the clinical outcomes of patients. 

This was a module in which the information was more advanced, solely due to the fact that it was a very unfamiliar topic for me. Unfortunately, it really did not have applicability to my clinical practice, however, who knows what will become of this area over the next few years. I am very curious to see if there will ever be wide stream clinical applicability of this topic.

#ASHPcerts
0 comments
1037 views

Permalink